These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 12214238)

  • 1. RNA aptamers as reversible antagonists of coagulation factor IXa.
    Rusconi CP; Scardino E; Layzer J; Pitoc GA; Ortel TL; Monroe D; Sullenger BA
    Nature; 2002 Sep; 419(6902):90-4. PubMed ID: 12214238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA as drug and antidote.
    Tuddenham E
    Nature; 2002 Sep; 419(6902):23-4. PubMed ID: 12214216
    [No Abstract]   [Full Text] [Related]  

  • 3. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
    Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
    Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
    Nimjee SM; Keys JR; Pitoc GA; Quick G; Rusconi CP; Sullenger BA
    Mol Ther; 2006 Sep; 14(3):408-15. PubMed ID: 16765093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway.
    Gopinath SC; Shikamoto Y; Mizuno H; Kumar PK
    Thromb Haemost; 2006 May; 95(5):767-71. PubMed ID: 16676065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of aptamers as anticoagulants.
    Nimjee SM; Rusconi CP; Harrington RA; Sullenger BA
    Trends Cardiovasc Med; 2005 Jan; 15(1):41-5. PubMed ID: 15795162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
    Bompiani KM; Monroe DM; Church FC; Sullenger BA
    J Thromb Haemost; 2012 May; 10(5):870-80. PubMed ID: 22385910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
    Chan MY; Cohen MG; Dyke CK; Myles SK; Aberle LG; Lin M; Walder J; Steinhubl SR; Gilchrist IC; Kleiman NS; Vorchheimer DA; Chronos N; Melloni C; Alexander JH; Harrington RA; Tonkens RM; Becker RC; Rusconi CP
    Circulation; 2008 Jun; 117(22):2865-74. PubMed ID: 18506005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidote-controlled DNA aptamer modulates human factor IXa activity.
    Fang L; Jin J; Zhang Z; Yu S; Tian C; Luo F; Long M; Zuo H; Lou S
    Bioorg Chem; 2024 Jul; 148():107463. PubMed ID: 38776649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
    Tanaka KA; Szlam F; Rusconi CP; Levy JH
    Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidote-mediated control of an anticoagulant aptamer in vivo.
    Rusconi CP; Roberts JD; Pitoc GA; Nimjee SM; White RR; Quick G; Scardino E; Fay WP; Sullenger BA
    Nat Biotechnol; 2004 Nov; 22(11):1423-8. PubMed ID: 15502817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor.
    Becker RC; Oney S; Becker KC; Sullenger B
    Ann N Y Acad Sci; 2009 Sep; 1175():61-70. PubMed ID: 19796078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversing anticoagulants both old and new.
    Warkentin TE; Crowther MA
    Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex.
    Sheehan JP; Lan HC
    Blood; 1998 Sep; 92(5):1617-25. PubMed ID: 9716589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa.
    Sheehan JP; Kobbervig CE; Kirkpatrick HM
    Biochemistry; 2003 Sep; 42(38):11316-25. PubMed ID: 14503882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anticoagulant with light-triggered antidote activity.
    Heckel A; Buff MC; Raddatz MS; Müller J; Pötzsch B; Mayer G
    Angew Chem Int Ed Engl; 2006 Oct; 45(40):6748-50. PubMed ID: 16983715
    [No Abstract]   [Full Text] [Related]  

  • 17. Aptamers: the emerging class of future anticoagulation for vascular disease.
    Kuliczkowski W; Floyd J; Malinin A; Serebruany V
    Expert Rev Cardiovasc Ther; 2010 Apr; 8(4):503-7. PubMed ID: 20397824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor IXa inhibitors as novel anticoagulants.
    Howard EL; Becker KC; Rusconi CP; Becker RC
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):722-7. PubMed ID: 17272750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new anticoagulant-antidote pair: control of thrombin activity by aptamers and porphyrins.
    Joachimi A; Mayer G; Hartig JS
    J Am Chem Soc; 2007 Mar; 129(11):3036-7. PubMed ID: 17319665
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.
    Soule EE; Bompiani KM; Woodruff RS; Sullenger BA
    Nucleic Acid Ther; 2016 Feb; 26(1):1-9. PubMed ID: 26584417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.